NoeticInsight

👉How Will AI Affect R&D? The question isn’t “will” AI affect R&D, but “how.” 🚨Pharma leaders, are you equipped to incorporate AI into your strategy? For a partner who understands the value of data, look to NoeticInsight. Get started at hubs.li/Q049jtTd0 #AI #pharma

🌺This is our last call for sponsors for the PRIMO Annual Meeting—lock in your opportunity now! Your role as a sponsor means you’re supporting discussions that will shape the future of oncology. Visit: hubs.li/Q047yD4_0 for more info. #PRIMO #oncology #immunotherapy

🌴Onviv Maui is calling…And so are cancer care experts! The PRIMO Annual Meeting is happening in Maui, Hawaii on April 8-11—you won’t want to miss it! There’s still time to sign up! hubs.li/Q047yvCQ0 #Onviv #oncology #immunotherapy #PRIMOmeeting

🚨We’re tuning in to all that the sessions at AAD has to offer this year. Will this be the year you transform your congress experience? See you at AAD! #AAD2026 #dermatology

👉The Mayo Clinic has shared some of their greatest strides from 2025. ⭐Are you prepared to take immediate action in the rapidly evolving healthcare industry? Connect with us to see new possibilities: hubs.li/Q046n3Tk0 Read more at: hubs.li/Q046n4xp0 #healthcare

In a trial, pembrolizumab cut the risk of disease progression or death by 28% and reduced death risk by 24% vs placebo plus paclitaxel. Want unbiased insight into what this could mean for your strategy? Connect with us: hubs.li/Q046npRk0 Source: hubs.li/Q046nhrk0

💭Imagine your brand here... PRIMO Hawaii convenes oncology leaders, KOL faculty, and practicing clinicians for meaningful clinical dialogue and networking. A limited number of sponsorship placements remain for the PRIMO Annual Meeting. 👉 Explore: hubs.li/Q045Pnj50

Know an extraordinary woman advancing cancer care? Nominate her for the 2026 Women in Oncology Award at PRIMO Hawaii. Recognize her impact, leadership, and dedication. 🌺 👉For more info and form: primomeeting.org/women-in-oncol… @hoperugo @rachnatshroff @PRIMOmeeting #WomeninOncology

#Breaking: @US_FDA approved our new combination regimen as the first and only all-oral, fixed-duration treatment for previously untreated adults with chronic lymphocytic leukemia (CLL). Learn more: gene.com/media/press-re…

📃A study published in AACR analyzed major modifiable cancer risk factors in the years before and after the COVID-19 pandemic. 🚨Interested in exploring this study with an expert? Get connected with NoeticInsight: hubs.li/Q03Yxl2c0 #riskfactors hubs.li/Q03YxrmL0

👉As a PRIMO Meeting or Summits sponsor, you support learning and development for practitioners and help them understand how to integrate immuno and molecular therapies into their practices. 🫁Learn more about our upcoming #lungcancer summit! hubs.li/Q03XWYMf0 #PRIMO

🌟We are eagerly anticipating the largest breast cancer research meeting in the world! When you need to turn the wealth of knowledge into practical applications and useful summaries, turn to NoeticInsight: hubs.li/Q03XmQ-50 #NoeticInsight #SABCS25

💡There will be 5000+ abstracts at ASH 2025, and we’ll be gathering insights to help inform how clinical practice will be affected. If you’re looking to make the most of your congress experiences, learn more about Noetic Insight: hubs.li/Q03XmWnc0 #NoeticInsight #ASH25

💊Have you been staying on top of novel drug approvals this year? These products have been approved for various cancers and diseases. ⭐For rapid access to data and insights, get started with NoeticInsight: hubs.li/Q03TV85n0 #FDA Source: hubs.li/Q03TV75C0

⭐The STARS trial findings support stereotactic radiation as an alternative to surgery, offering patients a less-invasive option to treat their lung cancer. 👉Access data faster and more efficiently with NoeticInsight: hubs.li/Q03T2rnV0 Source: hubs.li/Q03T2wlq0

👉As a #PRIMO sponsor, you can support learning and development for oncology practitioners and help them understand how and when to integrate immuno and molecular therapies into their practices. @PRIMOmeeting 🔍Get Started today: hubs.ly/Q03SVMZR0 #immunotherapy #oncology

👉In the MARIPOSA trial, 3-year overall survival with amivantamab–lazertinib in EGFR-mutated advanced NSCLC was 60% compared to 51% in the patient population receiving osimertinib. 📌Learn more about our services: hubs.li/Q03QR3rG0 #nsclc Source: hubs.li/Q03QRdc80

In a fast-moving market, pharma teams need to move with speed and clarity. With access to on-demand expert insights, NoeticInsight helps you adapt, launch, and lead with confidence. Connect to learn more: hubs.li/Q03L9KKw0 #MarketResearch #ClinicalAffairs #NoeticInsight

📌PRIMO creates a place for exchanging insights and key developments about the latest cancer innovations with attendees including faculty, US practicing clinicians, decision makers, and prescribers. Learn more! hubs.li/Q03N9kHG0 #noeticinsight #cancerinnovation

🌍 The global healthcare market is projected to reach $15.8T by 2025, fueled by innovation, chronic conditions, and demographic shifts. Learn more about healthcare market research and how to stay ahead: hubs.li/Q03L9Fqn0 #PharmaInsights #MarketResearch